Abstracts tagged "Early Rheumatoid Arthritis"

Abstract Number: 72 • 2018 ACR/ARHP Annual Meeting
Altered Serologic Responses to Epstein Barr Virus Precede Clinical Disease Development in Rheumatoid Arthritis
Heather M. Berens¹, Elizabeth A. Bemis², M. Kristen Demoruelle¹, John B. Harley³, Judith A. James⁴, Jess Edison⁵, Kevin D. Deane¹, Jill M. Norris⁶ and V. Michael Holers¹, ¹Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Division of Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ⁶Department of Epidemiology, Colorado School of Public Health, Aurora, CO
Background/Purpose: EBV infects B cells and is associated with several autoimmune diseases, including RA. Prior studies have shown that patients with active classified RA…
Abstract Number: 1492 • 2018 ACR/ARHP Annual Meeting
Methotrexate Response in Early Rheumatoid Arthritis Predicted Using a Somamer Proteomic Assay
Carol Hitchon¹, Victor Spicer¹, Nathalie Carrier², Ang Gao¹, Hani El-Gabalawy¹, John Wilkins¹ and Gilles Boire³, ¹University of Manitoba, Winnipeg, MB, Canada, ²Centre intégré universitaire de santé et de services sociaux de l'Estrie -Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ³Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: Available clinical tools do not adequately identify treatment non-responders in early rheumatoid arthritis (RA) leading to delayed disease control. Tools informed by molecular phenotype…
Abstract Number: 310 • 2018 ACR/ARHP Annual Meeting
The Trajectory of Grade 1 Erosions in the Feet of Patients with Early RA
Mary-Clair Yelovich¹, Hanyan Zou¹, Siobhan Deshauer¹, Saara Totterman², Karen A. Beattie³ and Maggie Larche⁴, ¹McMaster University, Hamilton, ON, Canada, ²Qmetrics Technologies, Pittsford, NY, ³Medicine, McMaster University, Hamilton, ON, Canada, ⁴St Joseph's Healthcare Hamilton, Hamilton, ON, Canada
Background/Purpose: The identification of erosions plays a critical role in the management of RA, as the presence of erosions denotes more aggressive disease requiring more…
Abstract Number: 1493 • 2018 ACR/ARHP Annual Meeting
Clinical Predictor Factors Associated with Sustained Disease Activity Among Patients with Early Rheumatoid Arthritis
Gabriela Gonzalez and Juan Molina, Rheumatology, La Paz University Hospital, Madrid, Spain
Background/Purpose: in rheumatoid arthritis (RA) patients the disease outcome has an unpredictable course and may differ even with an early diagnosis and treatment. Low disease…
Abstract Number: 313 • 2018 ACR/ARHP Annual Meeting
Do Musculoskeletal Ultrasound and Magnetic Resonance Imaging Identify Synovitis and Tenosynovitis at the Same Joints and Tendons? – a Comparative Study in Patients Presenting with Early Arthritis and Clinically Suspect Arthralgia
Aleid C. Boer¹, Sarah Ohrndorf², Debbie M. Boeters¹, Robin M ten Brinck¹, Gerd R. Burmester², Marion Kortekaas¹ and Annette H.M. van der Helm-van Mil^1,3, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ³Department of Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: In the diagnostic process of RA, the use of advanced imaging techniques like musculoskeletal ultrasound (US) and magnetic resonance imaging (MRI) has been recommended.…
Abstract Number: 1934 • 2018 ACR/ARHP Annual Meeting
microRNA Targeting IL-33 Gene As Biomarker to Predict Subclinical Atherosclerosis in Patients with Early Rheumatoid Arthritis
Isaac T. Cheng¹, Qing Shang², Jiayun Shen³, Martin Li³, Queenie Mak², Kitty Y Kwok⁴, Isaac CW Yim⁵, Edmund Kwok Ming Li², Priscilla Wong¹, Ronald ML Yip⁶, Steve H Pang⁶ and Lai-Shan Tam⁷, ¹Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, China, ²Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ³Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁴Department of Medicine, Queen Elizabeth Hospital, Hong Kong, Hong Kong, ⁵Department of Medicine, Tseung Kwan O Hospital, Hong Kong, Hong Kong, ⁶Department of Medicine, Kwong Wah Hospital, Hong Kong, Hong Kong, ⁷Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, Hong Kong
Background/Purpose: Patients with RA had increased risk of cardiovascular disease (CVD). Interleukin 33 (IL-33) plays an important role in pathogenesis of RA and development of…
Abstract Number: 533 • 2018 ACR/ARHP Annual Meeting
Association between Inflammation and Changes in Kidney Function in Patients with Early Rheumatoid Arthritis
Ganna Prytkova¹, Dmytro Rekalov² and Daryna Nikitina¹, ¹Rheumatology, Zaporizhzhya Regional Clinical Hospital, Zaporizhzhya, Ukraine, ²Department of Internal Diseases, Zaporizhzhya Regional Clinical Hospital, Zaporizhzhya, Ukraine
Background/Purpose: One of the most severe visceral manifestations of RA is nephropathy. The key symptoms of renal dysfunction (RD) are microalbuminuria (MA), β-2-microglobulinuria (β-2M), reduced…
Abstract Number: 2505 • 2018 ACR/ARHP Annual Meeting
Sociodemographic Factors Are Predictors of Poorer Clinical Outcome Trajectories in Early Rheumatoid Arthritis: Results from the Singapore Early Arthritis Cohort
Yuhan Zou¹, Peter P.M. Cheung^2,3, Lay Kheng Teoh⁴ and Manjari Lahiri^2,3, ¹Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ²Division of Rheumatology, University Medicine Cluster, National University Hospital, Singapore, Singapore, Singapore, ³Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ⁴National University Hospital, Division of Rheumatology, University Medicine Cluster, Singapore, Singapore
Background/Purpose: Variable outcomes in early rheumatoid arthritis (ERA) may be explained by heterogeneous latent disease activity trajectories, the predictors of which are not well defined.…
Abstract Number: 563 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Abatacept in Combination with MTX in Early, MTX-Naïve, Anti-Citrullinated Protein Antibody–Positive Patients with RA: Primary and 1-Year Results from a Phase IIIb Study
Paul Emery¹, Yoshiya Tanaka², Vivian P. Bykerk³, Tom W.J. Huizinga⁴, Gustavo Citera⁵, Marleen Nys⁶, Sean E. Connolly⁷, Alyssa Johnsen⁷ and Roy Fleischmann⁸, ¹University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Hospital for Special Surgery, New York, NY, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁶Bristol-Myers Squibb, Braine L’Alleud, Belgium, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: In patients (pts) with early (disease duration ≤24 months [mths]), MTX-naïve RA and poor prognostic factors including anti-citrullinated protein antibody (ACPA) positivity (+), abatacept…
Abstract Number: 2845 • 2018 ACR/ARHP Annual Meeting
A Close Relationship between a Novel Visceral Adiposity Index and Bone Microstructure in Female Early Rheumatoid Arthritis Patients: A 1-Year Follow-up Study By HR-pQCT
Jiang Yue^1,2, Priscilla Wong¹, James F Griffith³, Jiankun XU⁴, Fan XIAO⁵, Dongze Wu^1,2, Edmund Li¹, Lydia Ho Pui Tam⁶, Martin Li⁷, Tena K. Li¹, Tracy Y. Zhu⁸, Vivian W. Hung⁸, Ling Qin⁹ and Lai-Shan Tam¹⁰, ¹Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, China, ²Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ³Department of Imaging and Interventional Radiology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, ⁴Department of Orthopedics & Traumatology, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁵Department of Imaging and Interventional Radiology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁶Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁷Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁸Bone Quality and Health Centre of the Department of Orthopedics & Traumatology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, ⁹Bone Quality and Health Centre of the Department of Orthopaedics and Traumatology, The Prince of Wales Hospital, The Chinese University of Hong Kong, hongkong, Hong Kong, ¹⁰Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, Hong Kong
Background/Purpose: Background: Obesity has been traditionally considered to protect the skeleton against osteoporosis and fracture. Recently, body fat, specifically visceral adipose tissue (VAT), has been…
Abstract Number: 576 • 2018 ACR/ARHP Annual Meeting
An Analysis of Early Introduction of Adalimumab and Subsequent Bio-Free Condition in the Patients with Rheumatoid Arthritis
Satoshi Ito¹, Yoichi Kurossawa^1,2, Eriko Hasegawa^1,2, Daisuke Kobayashi^1,2, Shinji Taniguhi¹, Asami Abe¹, Hiroshi Otani¹, Kiyoshi Nakazono¹, Akira Murasawa¹, Ichiei Narita² and Hajime Ishikawa¹, ¹Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan, ²Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
Background/Purpose: HOPEFUL-1 trial showed efficacy of combination therapy with adalimumab (ADA) plus methotrexate (MTX) in MTX naïve patients with active early rheumatoid arthritis (eRA). In…
Abstract Number: 2873 • 2018 ACR/ARHP Annual Meeting
Remaining Pain and Widespread, Non-Inflammatory Pain Distribution during the First 12 Months after RA Diagnosis
Yvonne C. Lee¹, Orit Schieir², Marie-France Valois³, Susan J. Bartlett⁴, Gilles Boire⁵, Boulos Haraoui⁶, Carol A Hitchon⁷, Edward C. Keystone⁸, Diane Tin⁹, Carter Thorne¹⁰, Janet E. Pope¹¹ and Vivian P. Bykerk¹², ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²McGill University, Montreal, ON, Canada, ³McGill University, Montreal, QC, Canada, ⁴Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸Mount Sinai Hospital, Toronto, ON, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰University of Toronto, Newmarket, ON, Canada, ¹¹Department of Medicine, University of Western Ontario, London, ON, Canada, ¹²Hospital for Special Surgery, New York, NY
Background/Purpose: The incidence of fibromyalgia is highest in the first 12 months after RA diagnosis,1 indicating that this period may represent a critical window during…
Abstract Number: 588 • 2018 ACR/ARHP Annual Meeting
Acr Hybrid Analysis: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients with Early Rheumatoid Arthritis
Cristina Vitalini, Beatrice Barbetta, Giampaolo Giacovelli, Nadia Brambilla, Massimo D'Amato, Federica Girolami and Lucio C. Rovati, Clinical Research Department, Rottapharm Biotech, Monza, Italy
Background/Purpose: The ACR Hybrid, officially recommended by the ACR as a revision to the ACR20/50/70 response criteria, combines the ACR20/50/70 scores with the mean percent…
Abstract Number: 2898 • 2018 ACR/ARHP Annual Meeting
Increased Frequency of Circulating CD4+CXCR5-PD1hi Peripheral Helper T (cTph) Cells in Patients with Seropositive Early Rheumatoid Arthritis (RA)
Paula Fortea-Gordo¹, Laura Nuño², Alejandro Villalba², Diana Peiteado³, Irene Monjo⁴, Paloma Sanchez-Mateos⁵, Amaya Puig-Kröger⁶, Alejandro Balsa¹ and Maria Eugenia Miranda-Carus¹, ¹Rheumatology, Hospital La Paz - IdiPAZ, Madrid, Spain, ²Rheumatology, La Paz University Hospital, Madrid, Spain, ³Hospital Universitario La Paz, Madrid, Spain, ⁴Rheumatology, Rheumatology, La Paz University Hospital, Madrid, Spain, ⁵Immunology, Hospital Gregorio Marañon, Madrid, Spain, ⁶Immuno-oncology, Hospital Gregorio Marañon, Madrid, Spain
Background/Purpose: A novel population of CD4+ T cells with B cell helping capacity has been described in the synovial tissues and peripheral blood of seropositive…
Abstract Number: 589 • 2018 ACR/ARHP Annual Meeting
DAS28-CRP Versus DAS28-ESR and Thresholds for Disease Activity Category: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients with Early Rheumatoid Arthritis
Cristina Vitalini, Beatrice Barbetta, Giampaolo Giacovelli, Nadia Brambilla, Massimo D'Amato, Federica Girolami and Lucio C. Rovati, Clinical Research Department, Rottapharm Biotech, Monza, Italy
Background/Purpose: In most patients with rheumatoid arthritis (RA) the 28-Joint Disease Activity Score (DAS28) values calculated using C-reactive protein (CRP) are lower than those calculated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.